YMAB ymabs.com: Nilai Buku Perusahaan

The current market quotes for Y-mAbs Therapeutics (YMAB) visualized below demonstrate the asset's dynamics, with indicators currently at 0.09. Geopolitical fragmentation hinders the cross-border delivery of precision medicines and blocks global trials for rare pathologies. The business relies on the monopoly position of the drug Danyelza in neuroblastoma therapy, where strict FDA control shuts out competitors. The foundation of success is built on the brand's global recognition in pediatric oncology through the development of unique antibodies.

The fundamental value of Y-mAbs Therapeutics (YMAB) determines the objective threshold of the asset's investment attractiveness. The company's total book capitalization on GURU.Markets reflects the net asset value, excluding market volatility. This metric captures the real pace of capital expansion through asset accumulation. For Y-mAbs Therapeutics (YMAB), this indicator is critical due to its dependence on the drug Danyelza. The stability of this figure offsets the risks of regulatory delays in Europe and revenue concentration.